Sector News

Baxalta bets on ‘external innovation’ to meet its $8.5B goal and ward off Shire

August 21, 2015
Life sciences
Baxalta is hoping to launch 20 new drugs by 2020, and the nearly 2-month-old company is taking a decentralized approach to R&D on the way there, relying on partners to handle early-stage work before finishing projects itself.
 
Speaking to the Boston Business Journal, Baxalta R&D chief John Orloff said his company’s new hub in Cambridge, MA, is going to be far from a traditional research campus. Baxalta plans to house about 350 R&D workers at the site by 2016, but the company isn’t building a foot of lab space, keeping its in-house discovery unit in Europe. Instead, the Cambridge facility will be Baxalta’s dealmaking hub, Orloff said, seeking out partnerships that can widen the company’s pipeline.
 
“We are discovering that a lot of the discovery and basic research is being done in academia, is being done in biotech, and this is the hub of the biotech community,” Orloff told the BBJ. “… Our whole approach is one based on external innovation.”
 
Orloff’s words echo a great many of the multinational drugmakers piling into Cambridge, with newcomers like Eli Lilly and Bristol-Myers Squibb joining entrenched giants including Novartis and Biogen.
 
But Baxalta, thanks to an unwelcome buyout offer from Shire, has an air of immediacy with its pipeline work. About a week after the company completed its split from Baxter, Shire showed up with an unsolicited proposition to buy Baxalta for roughly $30 billion in stock, an offer the company refused. Last month, Shire went public with its pitch, betting it can convince Baxalta shareholders to force management into a conversation on the topic. Now Baxalta has gone on the defensive, touting its pipeline as undervalued and preaching patience to investors.
 
The company unveiled that 20-drug goal before its launch last month, projecting to add $2.5 billion in annual sales onto the roughly $6 billion in revenue it currently pulls in.
 
By Damian Garde
 
 

comments closed

Related News

April 26, 2024

Former Bristol Myers CEO tapped as Novartis’ next board chair

Life sciences

Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.

April 26, 2024

GE HealthCare launches voice-activated, AI-powered ultrasound machines for women’s health

Life sciences

GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.

April 26, 2024

Scientists reveal new method that could reduce waste from drug manufacturing

Life sciences

Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.

How can we help you?

We're easy to reach